| Budget Amount *help |
¥40,690,000 (Direct Cost: ¥31,300,000、Indirect Cost: ¥9,390,000)
Fiscal Year 2017: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2016: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
Fiscal Year 2015: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
Fiscal Year 2014: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Outline of Final Research Achievements |
Herpes simplex virus type 1 (HSV-1) can be genetically engineered to create oncolytic HSV-1 that can replicate selectively in and kill cancer cells. This project aimed to develop innovative oncolytic virus therapy that can cure malignant brain tumors. In order to target cancer stem cells, we created oncolytic HSV-1 that expresses TGF-β inhibitor or BMP4, a factor that inhibits the stemness of cancer stem cells. Further, to confer a high replication capability even in cancer stem cell-rich tumors or benign brain tumors, we created several oncolytic HSV-1 using tumor-specific promoters. Among newly created, armed oncolytic HSV-1 with a function to modify the brain tumor microenvironment, the one expressing anti-VEGF antibody showed an efficient antitumor activity without causing the tumor swelling that usually occurs after intratumoral virus administration, proving to be highly useful for the treatment of brain tumors.
|
